Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced lung cancer: durvalumab shows promise in trial

NCT ID NCT02087423

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 months, with the option to restart treatment if the cancer later progressed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could provide a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong
This is a phase 2 trial, so results are preliminary. The drug may not work for everyone and can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

446 people

The number who actually took part.

Started

Feb 2014

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged at least 18 years. * Documented evidence of NSCLC (stage IIIB/IV disease) * Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC * World Health Organisation (WHO) Performance Status of 0 or 1 * Estimated life expectancy of more than 12 weeks * Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3)) Exclusion Criteria: * Prior exposure to any anti-PD-1 or anti-PD-L1 antibody * Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids). * Active or prior autoimmune disease or history of immunodeficiency * Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. * Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. * Any unresolved toxicity CTCAE \>Grade 2 from previous anti-cancer therapy. * Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1 * Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Research Site

    Goodyear, Arizona, 85338, United States

  • Research Site

    Santa Rosa, California, 95403, United States

  • Research Site

    New Haven, Connecticut, 06511, United States

  • Research Site

    Port Saint Lucie, Florida, 34952, United States

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Lawrenceville, Georgia, 30046, United States

  • Research Site

    Waterloo, Iowa, 50701, United States

  • Research Site

    Topeka, Kansas, 66606, United States

  • Research Site

    Bethesda, Maryland, 20817, United States

  • Research Site

    Burlington, Massachusetts, 01803, United States

  • Research Site

    Worcester, Massachusetts, 01608, United States

  • Research Site

    Saint Louis Park, Minnesota, 55426, United States

  • Research Site

    New York, New York, 10011, United States

  • Research Site

    New York, New York, 10016, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    The Bronx, New York, 10461, United States

  • Research Site

    Huntersville, North Carolina, 28078, United States

  • Research Site

    Bismarck, North Dakota, 58501, United States

  • Research Site

    Fargo, North Dakota, 58102, United States

  • Research Site

    Blue Ash, Ohio, 45242, United States

  • Research Site

    Canton, Ohio, 44718, United States

  • Research Site

    Middletown, Ohio, 45042, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Fort Worth, Texas, 76104, United States

  • Research Site

    Spokane, Washington, 99208, United States

  • Research Site

    Wenatchee, Washington, 98801, United States

  • Research Site

    Vienna, 1145, Austria

  • Research Site

    Brussels, 1000, Belgium

  • Research Site

    Ghent, 9000, Belgium

  • Research Site

    Gilly, 6060, Belgium

  • Research Site

    Kortrijk, 8500, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Liège, 4000, Belgium

  • Research Site

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    London, Ontario, N6A 4L6, Canada

  • Research Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Regina, Saskatchewan, S4T 7T1, Canada

  • Research Site

    Brno, 656 53, Czechia

  • Research Site

    Prague, 14059, Czechia

  • Research Site

    Prague, 150 06, Czechia

  • Research Site

    Prague, 180 81, Czechia

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Brest, 29609, France

  • Research Site

    Créteil, 94010, France

  • Research Site

    Dijon, 21034, France

  • Research Site

    Le Mans, 72015, France

  • Research Site

    Marseille, 13015, France

  • Research Site

    Pessac, 33600, France

  • Research Site

    Rennes, 35033, France

  • Research Site

    Saint-Herblain, 44805, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Berlin, 10967, Germany

  • Research Site

    Berlin, 13585, Germany

  • Research Site

    Borstel, 23845, Germany

  • Research Site

    Cologne, 50924, Germany

  • Research Site

    Dortmund, 44263, Germany

  • Research Site

    Frankfurt am Main, 60590, Germany

  • Research Site

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    Großhansdorf, 22927, Germany

  • Research Site

    Hamburg, 20251, Germany

  • Research Site

    Heidelberg, 69126, Germany

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Győr, 9024, Hungary

  • Research Site

    Szolnok, 5000, Hungary

  • Research Site

    Tatabánya, 2800, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Candiolo, 10060, Italy

  • Research Site

    Catania, 95125, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Monza, 20900, Italy

  • Research Site

    Orbassano, 10043, Italy

  • Research Site

    Perugia, 06132, Italy

  • Research Site

    Pisa, 56124, Italy

  • Research Site

    Roma, 00144, Italy

  • Research Site

    Rozzano, 20089, Italy

  • Research Site

    Akashi-shi, 673-8558, Japan

  • Research Site

    Bunkyō City, 113-8603, Japan

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Habikino-shi, 583-8588, Japan

  • Research Site

    Hidaka-shi, 350-1298, Japan

  • Research Site

    Hirakata-shi, 573-1191, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Kitaadachi-gun, 362-0806, Japan

  • Research Site

    Kobe, 650-0047, Japan

  • Research Site

    Kōtoku, 135-8550, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Nagoya, 460-0001, Japan

  • Research Site

    Natori-shi, 981-1293, Japan

  • Research Site

    Osaka, 534-0021, Japan

  • Research Site

    Osaka, 541-8567, Japan

  • Research Site

    Sakaishi, 591-8555, Japan

  • Research Site

    Sayama, 589-8511, Japan

  • Research Site

    Sendai, 980-0873, Japan

  • Research Site

    Shinjuku-ku, 160-0023, Japan

  • Research Site

    Sunto-gun, 411-8777, Japan

  • Research Site

    Ube-shi, 755-0241, Japan

  • Research Site

    Yokohama, 236-0051, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Cebu City, 6000, Philippines

  • Research Site

    Quezon City, 0870, Philippines

  • Research Site

    Quezon City, 1100, Philippines

  • Research Site

    Quezon City, 1101, Philippines

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Singapore, 119228, Singapore

  • Research Site

    Singapore, 169610, Singapore

  • Research Site

    Singapore, 308440, Singapore

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Hwasun-gun, 58128, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 152-703, South Korea

  • Research Site

    Barcelona, 08908, Spain

  • Research Site

    Girona, 17007, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Seville, 41009, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Valencia, 46026, Spain

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Edinburgh, EH4 2XU, United Kingdom

  • Research Site

    London, EC1A 7BE, United Kingdom

  • Research Site

    Manchester, M20 4BX, United Kingdom

  • Research Site

    Stoke-on-Trent, ST4 6QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.